229961-08-4
Chemical Structure
Apelin-12
- CAS No.: 229961-08-4
- Formula:C64H103N21O14S
- Molecular Weight:1422.70
InChIKey: VNWKTOKETHGBQD-UHFFFAOYSA-N
SMILES: O=C([C@H]1N(CCC1)C(CNC([C@H](CCCCN)NC([C@@H](NC([C@H](CO)NC([C@H](CC(C)C)NC([C@H](CCCNC(N)=N)NC([C@H]2N(CCC2)C([C@@H](N)CCCNC(N)=N)=O)=O)=O)=O)=O)CC3=CN=CN3)=O)=O)=O)N[C@@H](CCSC)C(N4[C@@H](CCC4)C(N[C@H](C(O)=O)CC5=CC=CC=C5)=O)=O
Biological Activity: Apelin-12 is one of the most potent C-terminal fragments of the polypeptide that possesses a high affinity to orphan receptor APJ receptor. Apelin-12 is involved in the regulation of body fluid homeostasis and in the central control of feeding. Apelin-12 blocks HIV-1 entry through APJ receptor. Apelin-12 exerts neuroprotective effect[1][2][3].
| Cat. No. | Nom du produit | Pureté | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Apelin-12 | 99.83% | Apelin-12 is one of the most potent C-terminal fragments of the polypeptide that possesses a high affinity to orphan receptor APJ receptor. Apelin-12 is involved in the regulation of body fluid homeostasis and in the central control of feeding. Apelin-12 blocks HIV-1 entry through APJ receptor. Apelin-12 exerts neuroprotective effect. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Pisarenko OI, et al. Effects of structural analogues of apelin-12 in acute myocardial infarction in rats. J Pharmacol Pharmacother. 2013;4(3):198-203. [Content Brief]
- [2]. Pisarenko OI, et al. Apelin-12 and its structural analog enhance antioxidant defense in experimental myocardial ischemia and reperfusion. Mol Cell Biochem. 2014;391(1-2):241-250. [Content Brief]
- [3]. Liu DR, et al. Apelin-12 exerts neuroprotective effect against ischemia-reperfusion injury by inhibiting JNK and P38MAPK signaling pathway in mouse. Eur Rev Med Pharmacol Sci. 2018;22(12):3888-3895. Liu DR, et al. Apelin-12 exerts neuroprotective effect against ischemia-reperfusion injury by inhibiting JNK and P38MAPK signaling pathway in mouse. Eur Rev Med Pharmacol Sci. 2018;22(12):3888-3895. [Content Brief]
